CHRISTINA DALMADY-ISRAEL, PHARM.D.; PAUL J. GREEN, PH.D.; GARY E. SLOSKEY, PHARM.D.; PETER H. VLASSES, PHARM.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We read with interest the report of Graves and coworkers (1) about discrepancies among serum digoxin concentrations obtained by several different immunoassays in patients with renal impairment. We have recently seen assay-dependent differences between tobramycin serum concentrations in patients with renal failure who are receiving ticarcillin.
In nine serum samples from four patients (estimated creatinine clearances, 25 to 75 mL/min) receiving tobramycin and ticarcillin (8 to 18 g/d), we noted that the serum concentrations of tobramycin [see the Editor's note below] obtained by system A, a homogenous enzyme immunoassay (EMIT; Syva Company, Palo Alto, California), were consistently
DALMADY-ISRAEL C, GREEN PJ, SLOSKEY GE, et al. Ticarcillin and Assay of Tobramycin. Ann Intern Med. 1984;100:460–461. doi: 10.7326/0003-4819-100-3-460_2
Download citation file:
Published: Ann Intern Med. 1984;100(3):460-461.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use